title: Itch in Psoriasis Management.
abstract: Psoriasis is a common chronic inflammatory skin disease observed in about 1-3% of the general population. About 60-90% of patients with psoriasis suffer from itching. Interestingly, in the past itch was not considered as an important symptom of psoriasis. Despite the high frequency of itch in psoriasis, the pathogenesis of this symptom is still not fully elucidated. Although most studies indicate neurogenic inflammation and the role of neuropeptides, other mediators may be important as well. The majority of psoriatic patients consider itch as the most bothersome symptom of the disease as it significantly alters daily functioning and psychosocial well-being. Patients with itch showed greater impairment of their health-related quality of life compared to those without itch, and the intensity of itch correlated with the degree of quality-of-life reduction. However, treatment options for itch in psoriasis are limited. Therapy of itch in patients with psoriasis should be directed toward the resolution of skin lesions, as disease remission usually is linked with itch relief. Recent studies have clearly pointed to an important role of apremilast and biologic agents in itch intensity reduction in subjects suffering from psoriasis. Other treatment modalities include antihistamines, especially with a sedative effect, narrowband ultraviolet B, and antidepressants (doxepin, mirtazapine, paroxetine). Support by family members and/or health professionals may also be of importance in helping psoriatic subjects cope with itch.
authors: Jacek C
authors: JC
authors: Szepietowski
authors: Adam
authors: A
authors: Reich
mesh_terms: D000223:Adaptation, Psychological; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D004316:Doxepin / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000627:therapeutic use*; D006801:Humans; D008803:Mianserin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000078785:Mirtazapine; D017374:Paroxetine / Q000627:therapeutic use; D011537:Pruritus / Q000209:etiology / Q000523:psychology / Q000628:therapy*; D011565:Psoriasis / Q000150:complications / Q000523:psychology / Q000628:therapy*; D012944:Social Support; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014467:Ultraviolet Therapy
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000928:Antidepressive Agents; D006633:Histamine Antagonists; D004316:Doxepin; D008803:Mianserin; D017374:Paroxetine; D013792:Thalidomide; D000078785:Mirtazapine; C505730:apremilast